MICROPORT (00853) rose nearly 5%, reaching HK$10.61 by the time of writing, with a trading volume of HK$67.23 million. The company announced that MicroPort CardioFlow's independent shareholders approved the merger agreement and related transactions during a special general meeting held on December 15, 2025. The merger is expected to be completed on or around December 19, 2025, after which all existing issued shares (including ordinary and preferred shares) of CRM Cayman will be canceled in exchange for MicroPort CardioFlow's ordinary shares, making CRM Cayman a wholly-owned subsidiary of MicroPort CardioFlow.
The strategic merger is a key initiative to optimize resource allocation and enhance overall competitiveness, aiming to strengthen synergies in structural heart disease and cardiac rhythm management. By integrating complementary product lines and global distribution channels, the company will accelerate market penetration and improve operational efficiency. Leveraging its established overseas team and infrastructure, MICROPORT will further enhance localized service capabilities and supply chain resilience.
Comments